The lawsuit claims that ARS Pharmaceuticals misled shareholders by providing overly optimistic projections about securing CVS Caremark insurance coverage for its neffy product. According to the complaint, the company asserted that coverage would begin July 1, 2026, in time for the peak allergy seasons. Plaintiffs allege the firm concealed adverse facts about this timeline, causing stock to trade at artificially inflated prices until the reality of the situation surfaced.

The Rosen Law Firm, which filed the action, is currently soliciting participants for the class. Investors who purchased during the specified window may be eligible for compensation under a contingency fee arrangement. While no class has yet been certified, those interested in serving as a lead plaintiff must file their motion with the court by October 5, 2026. Legal counsel notes that investors retain the right to select their own representation or remain absent members of the class.